Immunovia AB announced positive feedback from its physician experience program for the IMMrayTM PanCan-d test in the U.S., which is nearing completion. The program has included 23 high risk surveillance centers around the U.S. thus far, and physicians have showed substantial interest in the use of IMMrayTM PanCan-d to detect early-stage pancreatic cancer. Immunovia's physician experience program was designed for providers in the U.S. to gain clinical experience using the IMMrayTM PanCan-d test.

Feedback from participating physicians suggests IMMrayTM PanCan-d is an important test for early detection of Pancreatic Cancer and their centers would like to incorporate the test into regular patient care. The novel test has been broadly adopted by physicians at the 23 high risk surveillance centers across the US and has contributed to more patients getting screened for early-stage pancreatic cancer. The company anticipates the completion of the initial physician experience program to occur before the end of the year.

Upon completion, the company intends to release a more comprehensive analysis of feedback and usage trends among initial participants. In September, Immunovia received a preliminary determination rate for IMMrayTM PanCan-d from The Centers of Medicare & Medicaid Services.